Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.

CONCLUSION: Tumor pseudoprogression occurred in 12.2% of patients with advanced stage lung cancer treated with nivolumab. An increase in lesion size or the appearance of new lesions must be assessed over time to avoid mistaking pseudoprogression for true progression of disease. PMID: 31300214 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31300214?dopt=Abstract

Source: Radiologia - July 8, 2019 Category: Radiology Authors: Mayoral M, Castañer E, Gallardo X, Andreu M, Dalmau E, Garcia Y Tags: Radiologia Source Type: research